Literature DB >> 15672865

Immunoblot analysis of c-Met expression in human colorectal cancer: overexpression is associated with advanced stage cancer.

Zhaoshi Zeng1, Martin R Weiser, Matt D'Alessio, Andrew Grace, Jinru Shia, Philip B Paty.   

Abstract

c-Met, the receptor of hepatocyte growth factor is known to be responsible for the motility and mitogenesis of epithelial cells including cancer cells. To investigate the significance of c-Met expression in human colorectal cancer (CRC), total cellular protein, extracted from 130 CRCs were examined by Western blot analysis. The signal was quantitated by ChemiImager 4000 Low Light Imaging System. c-Met expression was analyzed as the ratio of tumor to matched normal tissue (T/N) and expressed as fold-increase. The cellular localization of c-Met was assessed by immunohistochemistry. The T/N fold increase of c-Met varied from 0.2 to 10.7 with a mean of 3.41 +/- 0.23 (mean +/- SE). 69% primary CRC showed overexpression (T/N > 2.0) of c-Met. Significantly higher c-Met levels were found in CRC with blood vessel invasion (P = 0.04), and in advanced stage (P = 0.04). No relationship was noted between c-Met expression and age, tumor size, location, differentiation. C-Met immunoreactivity was observed in the membrane and cytoplasm of cancer cells. Positive staining of endothelial cells of blood vessels within normal submucosa and tumor was also evident. C-Met protein is expressed at levels significantly higher than adjacent mucosa in most primary adenocarcinomas of the colon. Our results support an important role for c-Met in human CRC progression and metastasis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15672865     DOI: 10.1007/s10585-005-1617-4

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  45 in total

1.  Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression.

Authors:  L Beviglia; K Matsumoto; C S Lin; B L Ziober; R H Kramer
Journal:  Int J Cancer       Date:  1997-06-20       Impact factor: 7.396

2.  Stage I rectal cancer: identification of high-risk patients.

Authors:  D Blumberg; P B Paty; A I Picon; J G Guillem; D S Klimstra; B D Minsky; S H Quan; A M Cohen
Journal:  J Am Coll Surg       Date:  1998-05       Impact factor: 6.113

3.  Tyrosine kinase receptor indistinguishable from the c-met protein.

Authors:  S Giordano; C Ponzetto; M F Di Renzo; C S Cooper; P M Comoglio
Journal:  Nature       Date:  1989-05-11       Impact factor: 49.962

4.  Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas.

Authors:  M F Di Renzo; M Olivero; T Martone; A Maffe; P Maggiora; A D Stefani; G Valente; S Giordano; G Cortesina; P M Comoglio
Journal:  Oncogene       Date:  2000-03-16       Impact factor: 9.867

5.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

Authors:  L Schmidt; F M Duh; F Chen; T Kishida; G Glenn; P Choyke; S W Scherer; Z Zhuang; I Lubensky; M Dean; R Allikmets; A Chidambaram; U R Bergerheim; J T Feltis; C Casadevall; A Zamarron; M Bernues; S Richard; C J Lips; M M Walther; L C Tsui; L Geil; M L Orcutt; T Stackhouse; J Lipan; L Slife; H Brauch; J Decker; G Niehans; M D Hughson; H Moch; S Storkel; M I Lerman; W M Linehan; B Zbar
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

6.  Comparison of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy.

Authors:  D Huntsman; J H Resau; E Klineberg; N Auersperg
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

7.  Expression of the HGF/SF receptor, c-met, and its ligand in human colorectal cancers.

Authors:  S E Hiscox; M B Hallett; M C Puntis; T Nakamura; W G Jiang
Journal:  Cancer Invest       Date:  1997       Impact factor: 2.176

Review 8.  Met-HGF/SF: tumorigenesis, invasion and metastasis.

Authors:  G F Vande Woude; M Jeffers; J Cortner; G Alvord; I Tsarfaty; J Resau
Journal:  Ciba Found Symp       Date:  1997

9.  Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas.

Authors:  C Liu; M Park; M S Tsao
Journal:  Oncogene       Date:  1992-01       Impact factor: 9.867

10.  In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis.

Authors:  F Silvagno; A Follenzi; M Arese; M Prat; E Giraudo; G Gaudino; G Camussi; P M Comoglio; F Bussolino
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-11       Impact factor: 8.311

View more
  17 in total

1.  Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.

Authors:  Alex A Adjei; Brian Schwartz; Edward Garmey
Journal:  Oncologist       Date:  2011-05-31

Review 2.  Prognostic value of c-Met in colorectal cancer: a meta-analysis.

Authors:  Yan Liu; Xiao-Feng Yu; Jian Zou; Zi-Hua Luo
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

3.  Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers.

Authors:  Surendra Pal Chaudhary; Eunice L Kwak; Jeffrey W Clark; Theodore S Hong; Katie L Hwang; Jochen K Lennerz; Ryan B Corcoran; Rebecca S Heist; Andrea L Russo; Aparna Parikh; Darrell R Borger; Lawrence S Blaszkowsky; Jason E Faris; Janet E Murphy; Christopher G Azzoli; Eric J Roeland; Lipika Goyal; Jill Allen; John T Mullen; David P Ryan; A John Iafrate; Samuel J Klempner
Journal:  Oncologist       Date:  2020-09-12

Review 4.  Gene dysregulations driven by somatic copy number aberrations-biological and clinical implications in colon tumors: a paper from the 2009 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  Manny D Bacolod; Francis Barany
Journal:  J Mol Diagn       Date:  2010-08-13       Impact factor: 5.568

5.  Molecular magnetic resonance imaging approaches used to aid in the understanding of the tissue regeneration marker Met in vivo: implications for tissue engineering.

Authors:  Rheal A Towner; Nataliya Smith; Yasuko Asano; Sabrina Doblas; Debra Saunders; Robert Silasi-Mansat; Florea Lupu
Journal:  Tissue Eng Part A       Date:  2010-02       Impact factor: 3.845

Review 6.  MET as a target for treatment of chest tumors.

Authors:  Nicole A Cipriani; Oyewale O Abidoye; Everett Vokes; Ravi Salgia
Journal:  Lung Cancer       Date:  2008-07-30       Impact factor: 5.705

7.  Suppression of Met activation in human colon cancer cells treated with (-)-epigallocatechin-3-gallate: minor role of hydrogen peroxide.

Authors:  Christine A Larsen; Roderick H Dashwood
Journal:  Biochem Biophys Res Commun       Date:  2009-09-08       Impact factor: 3.575

8.  c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases.

Authors:  Zhao-Shi Zeng; Martin R Weiser; Eleanor Kuntz; Chin-Tung Chen; Sajid A Khan; Ann Forslund; Garrett M Nash; Mark Gimbel; Yuka Yamaguchi; Alfred T Culliford; Matthew D'Alessio; Francis Barany; Philip B Paty
Journal:  Cancer Lett       Date:  2008-04-18       Impact factor: 8.679

9.  Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo.

Authors:  Edward Htun van der Horst; Lawrence Chinn; Min Wang; Timothy Velilla; Hoang Tran; Yarrow Madrona; Andrew Lam; May Ji; Timothy C Hoey; Aaron K Sato
Journal:  Neoplasia       Date:  2009-04       Impact factor: 5.715

10.  Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas.

Authors:  C Holgren; U Dougherty; F Edwin; D Cerasi; I Taylor; A Fichera; L Joseph; M Bissonnette; S Khare
Journal:  Oncogene       Date:  2010-07-26       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.